PHOENIX Pharma SE

PHOENIX group · Companies & groups · DE

Kategorija
Companies & groups
Būstinė
Mannheim DE
Registruota
2018-08-21
Deklaruotos metinės išlaidos
100 000–199 999 € (pačios deklaruota)
Svetainė
http://phoenixgroup.eu
Skaidrumo registras
108461232380-63 ↗
0
Susitikimai su EK
Pateiktos pozicijos
0
Pozicijos dokumentai
0
Paminėjimai spaudoje
Sumą deklaruoja pati organizacija Skaidrumo registre; institucijos jos netikrina.

Ką pateikė viešoms konsultacijoms

2026-09-09 · Implementing rules on registering in and reporting to the register of producers ↗ originalus šaltinis
PHOENIX remains supportive of the overall objectives of PPWR and welcomes further dialogue on practical implementation requirements for the Extended Producer Responsibility (EPR) process. The proposed reporting requirements depend on the availability of detailed packaging data that is often held by suppliers and contract manufacturers. Companies will therefore require sufficient time to establish the necessary packaging data governance frameworks, supplier engagement processes, data validation mechanisms, and digital infrastructure needed to collect, manage, and maintain reliable packaging information. PHOENIX supports the objective of improved packaging transparency; however, successful…
2026-03-13 · Simplification of administrative burdens in environmental legislation ↗ originalus šaltinis
To whom it may concern, PHOENIX group welcomes the goal of the new Commissions term aimed at reducing administrative burden and making European business environment more competitive in the light of unprecedented geopolitical pressures. We further welcome the opportunity to share our position on the administrative burdens in environmental legislation. Against this background, please find attached our latest submission. Should you have any questions, please let us know directly. Kind regards, Gavrilo Nikolic Head of Public Affairs for the PHOENIX group

Kokias ES temas nurodo sekanti

PHOENIX group will take an active interest in all topics that have a direct or indirect impact on our core and emerging business sectors.
The General Pharmaceutical Regulations Review
All eHealth mHealth initiatives
Healthy Ageing
Falsified Medicines Directive
Shortages and Medicines Accessibility, Critical Medicines Act, Stockpiling initiatives
Cross Border Services
Healthcare Innovation and Services Development
All other relevant Directives and legislative developments